Recent studies demonstrate that the receptor tyrosine kinase (TK) Ron is tumorigenic when overexpressed and plays a role in regulating skin homeostasis. We hypothesized that Ron signaling promotes skin carcinogenesis. To test this hypothesis, mice deficient in the TK domain of Ron (TK À/À mice) were crossed with v-Ha-ras (Tg.AC) transgenic mice; the resulting TK À/À Tg.AC þ /À mice, and their controls, were utilized in a model of chemically induced Ras-mediated skin carcinogenesis. The mice were treated with 2.5 lg of 12-O-tetradecanoylphorbol-13-acetate applied weekly to the shaved back of 36 control (TK
Introduction
The tyrosine kinase (TK) receptor, Ron, is a heterodimeric glycoprotein with disulfide-linked a and b chains of 35 and 150 kDa, respectively. The cell surface receptor contains an extracellular, a transmembrane and an intracellular TK domain. The structure of Ron places it in a family of multifunctional TK receptors that includes the proto-oncogenes, c-Met and c-Sea. Activation of Ron elicits diverse biological responses including cell-cell dissociation, cellular proliferation, motility and invasiveness. Recent studies suggest that Ron may play a role in regulating skin homeostasis (Wang et al., 1996a; Nanney et al., 1998; Waltz et al., 1998) . Ron expression has been documented in the epidermis, hair follicles and the ducts of sweat glands in the skin (Nanney et al., 1998) . The ligand for Ron, hepatocyte growth factor-like protein/macrophage-stimulating protein (HGFL), has been shown to stimulate not only the proliferation of murine keratinocytes and established keratinocyte cell lines but also the migration of keratinocytes on collagen substratums (Wang et al., 1996a) . HGFL has been shown to induce Ron activation in both primary keratinocytes and in neoplastic keratinocyte cell lines that resemble papillomas and carcinomas histologically. In addition to its effect in cell lines, recent studies have demonstrated that HGFL increases dramatically in wound fluids from human burn patients and that Ron expression is significantly upregulated during the wound healing response (Nanney et al., 1998) . Further, Ron overexpression has been documented in a number of human cancers, including hepatocellular carcinomas (Chen et al., 1997) , primary human non-small-cell lung carcinomas (Willett et al., 1997) , malignant human colonic mucosa and breast carcinomas Maggiora et al., 1998; Okino et al., 1999; Wang et al., 2000) . Our laboratory has recently shown that overexpression of wild-type Ron or activating mutations in Ron is sufficient to induce increased receptor phosphorylation and transformation of NIH3T3 cells to malignant phenotypes . These transformed cell lines exhibit oncogenic potential, indicating that Ron may behave as an oncogene when overexpressed or activated by mutations.
Based on the function of Ron in skin and increasing evidence that Ron may behave as an oncogene when overexpressed or activated, we hypothesized that loss of Ron signaling would decrease the progression of skin cancer. To test our hypothesis, we generated v-Ha-Ras transgenic (Tg.AC) mice deficient in the Ron TK domain (TK À/À Tg.AC þ /À ) and utilized them in a wellcharacterized mouse model of chemically induced skin carcinogenesis (Spalding et al., 1993 (Spalding et al., , 1999 . Utilizing this model, we explored the role of Ron in the initiation, promotion and progression of skin tumors. Our studies document for the first time that Ron signaling has a significant impact in the growth and malignant progression of papillomas in a mouse model of chemically induced skin carcinogenesis.
Results

Ron regulates papilloma growth and number but not the time to formation
To test the hypothesis that Ron signaling influences the initiation and promotion of skin tumors, we generated
) mice. These mice were subjected to 12-O-tetradecanoylphorbol-13-acetate (TPA) treatment for 10 weeks. Although the kinetics of papilloma formation between the control and experimental group are similar (Figure 1a ), the number of papillomas induced is significantly greater in the TK À/À Tg.AC þ /À mice ( Figure 1b) . Strikingly, from week 7 to 13, the average papilloma volume from the TK À/À Tg.AC þ /À mice was significantly reduced compared to that of the Figure 2a reflects that the average papilloma volume of the largest papillomas from the TK À/À Tg.AC þ /À mice is significantly reduced compared to controls; meanwhile, Figure 2b shows that the representative average volume of the papillomas in the TK À/À Tg.AC þ /À mice is also significantly reduced. After week 13, the growth of the TK þ / þ Tg.AC þ /À papillomas slowed while the TK À/À Tg.AC þ /À papillomas continued to grow until the difference in size between the two groups was no longer statistically significant (Figure 2a These data are consistent with the growth curve presented in Figure 2a . Most strikingly, the proliferation indexes in the TK À/À Tg.AC þ /À papillomas never reach the peak levels observed in the TK 
Tg.AC
þ /À papillomas is not increased to the level seen in the TK þ / þ Tg.AC þ /À papillomas. We analysed a total of seven independent papillomas from a number of TK À/À Tg.AC þ /À mice and detected a reduced level of Ron protein expression in five of these papillomas when compared to papillomas from the wild-type mice. We obtained similar results using an antibody that targets a different domain of Ron (data not shown). The pattern of Ron protein expression is consistent between Western and immunohistochemical analyses. These data suggest that although the presence of Ron signaling does not affect Ras protein levels, upregulation of Ron in the papillomas is one of the mechanisms by which papilloma growth is regulated by Ron signaling. We also investigate if Ras upregulation directly leads to Ron overexpression. Ectopic expression of activated Ras in both NIH3T3 and PAM212 cells does not lead to Ron upregulation . Similarly, ectopic expression of a dominant-negative form of Ras (N17Ras) in PAM212 cells does not result in the downregulation of Ron expression (Figure 4d ). These results suggest that upregulation of Ron is not a direct result of Ras overexpression.
The absence of Ron signaling affects MAPK and Akt signaling
To explore the downstream biochemical pathways, which may account for the reduced growth in the TK À/À Tg.AC þ /À. papillomas, we performed Western analyses to analyse MAPK (Erk1/2) and Akt protein levels and phosphorylation status. Taking into account that variabilities of Ras protein levels in the papillomas will result in variabilities of MAPK activation since MAPK is a known downstream target of Ras, we normalized the degree of MAPK activation (p-MAPK per total MAPK) to the amount of Ras detected in the individual papilloma lysate. We performed Western analyses on a total of 16 sets of papilloma lysates (seven
. Although the differences in MAPK activation is subtle between the papilloma lysates from the control and experimental group, there is a consistent and statistically significant 25% reduction in the degree of MAPK activation in the TK À/À Tg.AC þ /À papillomas ( Figure 5a and b). On the other hand, the amount of phosphorylated MAPK is equivalent in the TPA-treated skin lysates from Tg.AC À/À mice regardless of Ron status. These results suggest that TPA activates MAPK independent of Ron, but Ron synergizes with Ras to activate MAPK signaling in the papillomas. Furthermore, we performed Western analyses to investigate the degree of Akt activation on a total of 14 sets of papilloma lysates (six
Tg.AC þ /À papillomas). We found that the degree of Akt activation (p-Akt per total Akt) was also significantly reduced in the TK À/À Tg.AC þ /À papillomas (Figure 5c and d). Again, Ron signaling does not affect the amount of phosphorylated Akt in the TPA-treated skin lysates from Tg.AC À/À mice, but phosphorylated Akt in the papilloma lysates from TK À/À Tg.AC þ /À mice is reduced by about 40%. These results indicate that TPA also activates Akt independent of Ron, but Ron signaling in the papillomas leads to full Akt activation.
Ron facilitates malignant conversion
Although the majority of nonmalignant papillomas regressed or sloughed off over time following TPA withdrawal, a small percentage of papillomas from both groups of mice progressed to malignant skin tumors, which exhibited either a spindle or squamous cell morphology. Interestingly, these Tg.AC þ /À mice also developed an array of other malignant tumor types 
Discussion
Ron is a member of a multifunctional TK receptor family containing the proto-oncogenes, Met and Sea. In this study, we demonstrate for the first time that Ron signaling has a significant impact in the growth and malignant progression of papillomas in a mouse model of chemically induced skin carcinogenesis.
Although there is no difference in the time to onset of papilloma formation in the TK À/À Tg.AC þ /À mice compared to controls, individual papilloma growth rate is significantly impaired in the TK À/À Tg.AC þ /À mice. The reduction in growth rate is associated with a reduction in cellular proliferation. The proliferation indexes are lower in the TK À/À Tg.AC þ /À papillomas. As TPA application ceases, the proliferation index slowly declines and the growth of the papillomas plateaus. With time, the TK À/À Tg.AC þ /À papillomas slowly reach the size of TK þ / þ Tg.AC þ /À papillomas. Nevertheless, the proliferation index in the TK À/À Tg.AC þ /À papillomas never reaches the peak level attained by the TK
Tg.AC þ /À papillomas during the course of papilloma growth. These data indicate that there is a defect in cellular proliferation in the TK À/À Tg.AC þ /À papillomas as a result of loss of Ron signaling.
Since Ras is known to be upregulated in the papillomas of this model and activated Ras drives An alternative mechanism for papilloma growth in our model may involve the dysregulation of Ron. This rationale is based on reports of an association between Ras and Met. Ectopic expression of activated Ras has been shown to induce significant expression of Met in C127 and NIH3T3 cells as well as in human thyroid epithelial cells (Ivan et al., 1997; Webb et al., 1998) . Further, dominant-negative mutants of Met inhibit cell invasion as well as metastatic potential of Ras-transformed cells (Furge et al., 2001 Activation of Ron has been shown to activate MAPK, a well-known regulator of cell proliferation (Santoro et al., , 1998 . When we investigated the activation and protein levels of MAPK in the papillomas, we found a statistically significant but subtle 25% reduction in phosphorylated MAPK in the papilloma lysates from TK À/À Tg.AC þ /À mice. Since papilloma growth is not completely abolished in the TK À/À Tg.AC þ /À mice, this result is consistent with the conclusion that Ron synergizes with Ras to fully activate the MAPK pathway in the papilloma. With a defect in Ron signaling, papilloma growth is impaired as a result of partial defect in the activation of MAPK. Our finding is also consistent with the in vitro analysis of Friend virus-infected erythroblasts (Finkelstein et al., 2002) . The addition of a MEK inhibitor, which blocks the activation of MAPK, resulted in a decrease in Friend virus-induced colony formation from Ron-transduced Fv2 rr bone marrow cells (Finkelstein et al., 2002) . Phosphatidylinositol-3-kinase (PI3K) has also been shown to interact with the Ron receptor (Iwama et al., 1996; Wang et al., 1996b) . In contrast to signaling by other growth factors, where PI3K activation is Ras dependent (Rodriguez-Viciana et al., 1994) , activated Ron binds PI3K directly and stimulates its catalytic activity (Wang et al., 1996b) . Akt is a known downstream signaling component of PI3K (Franke et al., 1997) . Thus, we sought to explore the activation and protein levels of Akt in the papillomas. We observed a statistical significant 40% decrease in the activation of Akt in the TK À/À Tg.AC þ /À papillomas, indicating that the absence of Ron signaling results in a defect in the activation of the Akt pathway. Since the PI3K/Akt pathway is involved with cellular proliferation, the reduction in activated Akt suggests that the reduction of papilloma growth in the TK À/À Tg.AC þ /À mice is partly due to the defect in this signaling pathway. Our finding is again consistent with in vitro analyses of this pathway by other investigators. A decrease in cell growth and colony formation in soft agar was seen after blocking the PI3K/Akt signaling pathway in v-Seatransfected cell lines (Agazie et al., 2002) . Similarly, increased activation of Akt was observed in NIH3T3 cells expressing constitutively active truncated forms of Ron, and by blocking the activation of PI3K, gp55-mediated growth of Friend virus-infected erythroblasts was inhibited (Finkelstein et al., 2002) .
In addition to MAPK and Akt signaling pathways, we also investigate if the absence of Ron receptor signaling is associated with changes in the expression level of other signaling molecules. We did not detect appreciable differences in the expression level of b-catenin, MYC, cyclin D1 and p27 between the TK
Over time, the majority of the papillomas regressed or sloughed off following withdrawal of TPA treatment. Other studies have shown that subpopulations of papillomas at high risk for malignant progression do not regress and have a 3-6-fold increase in BrdU labeling (Hennings et al., 1985 (Hennings et al., , 1990 . Since the TK À/À Tg.AC þ /À papillomas have a reduced BrdU labeling index, we expected to see a reduction in the frequency of malignant conversion in the TK À/À Tg.AC þ /À papillomas. In fact, the frequency of papillomas progressing to malignant skin tumors is reduced in the TK À/À Tg.AC þ /À papillomas. Interestingly, Tg.AC þ /À mice also develop other malignant tumor types (Cardiff et al., 1993) . The TK À/À Tg.AC þ /À mice are resistant to the development of these other tumors. Thus, Ron receptor signaling appears to be important in the formation of these alternative tumor types.
We were surprised to find that there are significantly more papillomas in the TK À/À Tg.AC þ /À mice. This result suggests that Ron signaling may play a different role in the initial formation of papillomas as compared to the growth of the papillomas once they reach a certain stage. Although we did not pursue the mechanisms underlying the increased number of papillomas in this current study, we speculate that the phenomenon may be related to the altered inflammatory responses in the TK À/À mice Leonis et al., 2002; McDowell et al., 2002) since inflammatory cytokines have been shown to be involved with the process of papilloma formation. For example, TNF-a null mice developed significantly less number of papillomas in the two-stage chemically induced skin carcinogenesis model (Moore et al., 1999) .
In summary, we demonstrated for the first time that Ron signaling augments papilloma growth and malignant transformation in vivo, a finding that has clinical implications. Although there have been some reports of overexpression or alterations in Ron in human cancers, the role of Ron in human skin malignancies is unknown. The malignant skin tumors in this model closely resemble the human equivalent of squamous cell carcinoma and malignant fibrous histiocytoma (Leder et al., 1990) ; some of these human skin cancers have the same H-ras mutation as in our model (Pierceall et al., 1991; Spencer et al., 1995; Bohle et al., 1996; Sakamoto et al., 2001) . Therefore, it may be worthwhile to extrapolate and investigate the status of Ron in human skin carcinomas.
Materials and methods
Animals and genotyping
Male Ras transgenic mice (Tg.AC, FVB/N strain) were purchased from Taconic (Germantown, NY, USA) and maintained in the Cincinnati Children's Research Foundation AAALAC approved animal facility. Mice containing the germline deletion of the TK domain of the Ron receptor (TK À/À mice) have been described previously . TK À/À mice express a truncated form of the Ron receptor containing only the extracellular and transmembrane domains. The TK À/À mice were backcrossed seven generations into an FVB/N genetic background and were bred with the Tg.AC ) were generated. For genotyping, DNA isolated from ear biopsies was utilized for polymerase chain reaction .
Chemical carcinogenesis protocol
TPA (Sigma Chemical Co., St Louis, MO, USA, 2.5 mg/week) was dissolved in 200 ml acetone and applied with micropipettes to the shaved back of 5-to 8-week-old mice twice weekly for a total of 10 weeks. A few mice from the experimental (TK
) groups were treated with acetone only. All mice were monitored for papilloma eruption twice weekly. Papillomas that persisted and grew to 1 mm in size were counted. The date of eruption of the first papilloma was recorded. The number of papillomas was recorded for each mouse weekly for 15 weeks. The size of the largest papilloma per mouse was measured in two dimensions weekly for 17 weeks. Tumor volume was calculated using the following formula: (length Â width 2 )/2 (Kulesz- Martin et al., 1991) . The sizes of multiple individual papillomas on the control and experimental mice were also measured at the different time points. A total of 20 random papillomas from each mouse were measured at week 8 and 13. A total of six mice each from the control and experimental groups at each time point were included in this analysis. The average volume of the individual papillomas from each TK À/À Tg.AC þ /À mouse was normalized to 1 when compared to the control counterpart. Then, the mice were monitored weekly for signs of malignant conversion of the papilloma such as deep ulceration, bleeding and induration. The mice were also monitored for signs of the development of other malignant tumor types such as jaw swelling, enlargement of lymph nodes and salivary glands. The percentage of papillomas undergoing malignant conversion was calculated as the total number of malignant skin tumors per total number of papillomas induced. Malignant skin tumors were first noted at 13 weeks; therefore, mice that were killed or found dead prior to this time point were not included in the analysis of malignant conversion.
Histology
Tissues were fixed in formalin, dehydrated, blocked in paraffin and sectioned at 6 mm. The tissue sections were stained with hematoxylin and eosin. Over 100 nonmalignant papillomas and all malignant tumors were examined. Malignant skin tumors were densely cellular spindle cell tumors in the dermis underlying the papilloma, often exhibiting invasion through skeletal muscle and sometimes associated with lymph node metastasis. Premalignant lesions were squamous cells showing atypia (enlarged nuclei, mitotic activity) but not associated with spindle cell proliferation, invasion or metastasis.
BrdU and Ron immunohistochemistry
Mice were injected with BrdU intraperitoneally and killed 2 h postinjection. Sections of papillomas were stained with antiBrdU monoclonal antibodies using standard procedures (Amersham Pharmacia Biotech, Buckinghamshire, England). Proliferation index was defined as the number of stained cells per total number of cells counted in multiple random highpower fields using a microscope grid. Over 1000 cells were counted from papillomas from each animal at different time points. The same set of mice in which papilloma number and volume were quantified were used in the BrDU analysis with a total of 29 TK þ / þ Tg.AC þ /À and 28 TK À/À Tg.AC þ /À mice available at the end of the BrDU study. A total of two different independent papillomas per mouse were examined at each time point. Sections of papillomas were also stained with a mouse antibody specific to the extracellular a chain of Ron (Ron a, BD Transduction Laboratories, San Diego, CA, USA).
Western analysis
Papillomas or total skin lysates were prepared from the indicated mice. Protein concentrations were quantified using Bradford assays. Proteins from total lysates were analysed by Western analyses. The antibodies used include: anti-Ras (BD Transduction Laboratories, San Diego, CA, USA), anti-aRon (BD Transduction Laboratories, San Diego, CA, USA), anti-MSPR (R&D Systems, Minneapolis, MN, USA), anti-C4 actin, anti-phospho-Akt/anti-Akt (Upstate, Lake Placid, NY, USA) and anti-phospho-MAPK/anti-MAPK (Cell Signaling, Beverly, MA, USA), anti-MYC (Invitrogen, CA, USA), anticyclin D1 (Santa Cruz Biotechnology, CA, USA), anti-bcatenin (BD Transduction Laboratories, San Diego, CA, USA), anti-p27KIP (Santa Cruz Biotechnology, CA, USA) and anti-HA.
Transfection
NIH3T3 and PAM212 cells were transfected using FuGENE 6 Transfection Reagent (Roche Applied Science, Indianapolis, IN, USA). In brief, cells were plated at a concentration of 1 Â 10 5 /well in a six-well plate. After 24 h, the FuGENE:DNA complex in antibiotic-free medium was added to the cells as per the manufacturer's recommendation. The cells were transfected with pDCR-HRas (containing a HRas cDNA into pDCR), HA-tagged N17Ras (Guthrie cDNA Resource Center, Sayre, PA, USA) and the corresponding control plasmid DNA, pDCR and pcDNA3. To assay for transient transfection, NIH3T3 and PAM212 cells were lysed the following day, protein concentrations were quantified using Bradford assays and the lysates were analysed by Western analyses for Ras and Ron protein expression using anti-Ras (BD Transduction Laboratories, San Diego, CA, USA), antiaRon (BD Transduction Laboratories, San Diego, CA, USA) and anti-MSPR (R&D Systems, Minneapolis, MN, USA) antibodies. For stable clones, NIH3T3 cells were transfected and selected in 600 mg/ml of G418 24 h post-transfection. After 7-10 days, distinct colonies were picked and expanded. Each colony was assayed for Ras protein expression. Colonies that stably overexpressed Ras were subsequently assayed for Ron protein expression by Western analysis.
Statistics and image analysis
Statistical comparisons were performed using analysis of variance (ANOVA) testing on all data except for the analysis on malignant transformation. Chi-squared (w 2 ) analysis was performed to compare the frequency of malignant conversion of papillomas and the number of mice with other malignant tumor types between the control and experimental groups. The software package StatView (SAS Institute) was utilized for statistical analyses. Quantitation of bands in Western analyses was performed with ImageQuant Software using the Storm Imaging System (Molecular Dynamics).
Abbreviations HGFL, hepatocyte growth factor-like protein; HGF, hepatocyte growth factor; TK, tyrosine kinase.
